Inside the Rise of circRNA
Circio CEO Erik Wiklund reflects on the discovery of human circular RNA and its evolution into a fast-moving therapeutic modality
Clinical Scorecard: Inside the Rise of circRNA
At a Glance
| Category | Detail |
|---|
| Condition | Circular RNA |
| Key Mechanisms | Stability and resistance to degradation pathways |
| Target Population | Researchers and drug developers |
| Care Setting | Biological research and therapeutic development |
Key Highlights
- Discovery of circular RNA in human cells in 2013 led to increased interest in its biological functions.
- Circular RNA is more stable than mRNA, making it a promising therapeutic modality.
- Companies like Laronde are developing circular RNA vaccines, attracting significant funding.
- Circular RNA functions as a microRNA sponge, regulating gene expression.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Not specified
Circular RNA is being explored as a therapeutic format due to its stability.
Clinical Best Practices
- Focus on the unique properties of circular RNA in therapeutic development.
- Leverage the stability of circular RNA for vaccine and treatment formulations.
Related Resources & Content
